References
- Faich G. A., Lawson D. H., Tilson H. H., et al. Clinical trials are not enough: Drug development and pharmacy epidemiology. J. Clin. Res. Drug Dev. 1987; 1: 75
- Wardell W. M., Tsianco M. C., Awavekar S. N., et al. Postmarketing surveillance of new drugs: I. Review of objectives and methodology. J. Clin. Pharmacol. 1979; 19: 85
- Faich G. A. Adverse drug reaction monitoring. N. Engl. J. Med. 1986; 314: 1589
- Sills J. M., Tanner L. A., Milstien J. B. Food and Drug Administration monitoring of adverse drug reactions. Am. J. Hosp. Pharm. 1986; 43: 2764
- Rossi A. C., Knapp D. E. Discovery of new adverse drug reactions: A review of the Food and Drug Administration's spontaneous reporting system. JAMA 1984; 252: 1030
- Venning G. R. Identification of adverse reactions to new drugs: II. How were 18 important adverse reactions discovered and with what delays?. Br. Med. J. 1983; 286: 365
- Drug monitoring, F. H. Gross, W. H.W. Inman. Academic Press, London 1977